Clinical trials: Metastatic Solid Tumor Cancer
Neoplasms
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
The goal of this clinical trial is to test a new medicine called GSK5764227, which delivers a toxin directly to cancer cells to destroy them while sparing healthy cells.
- Trial name
- NCT07277270
- Testing
- GSK5764227, Bevacizumab, Fluorouracil
- Where
- 22 sites in United States, Australia and 4 more
- Volunteers
- 83 people
- Sponsor
- GlaxoSmithKline
Locally Advanced Solid Tumor
Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors
This Study is a single arm, open label, multicenter phase III clinical trial to evaluate the safety and efficacy of VC004 in patients with locally advanced/metastatic solid tumors.
- Trial name
- NCT06658353
- Testing
- VC004 Capsules
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Mesothelioma, Glioblastoma
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
- Conditions
- Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT04913337
- Testing
- NGM707, NGM707 plus pembrolizumab (KEYTRUDA®)
- Where
- 27 sites in United States, South Korea and 1 more
- Volunteers
- 179 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Urinary System Tumor, Solid Tumor
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors
Phase IIa/IIb clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of BL-B01D1 for injection in patients with multiple solid tumors such as locally advanced or metastatic urinary system tumors.
- Trial name
- NCT05785039
- Testing
- BL-B01D1
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Kita-kyushu Lung Cancer Antigen 1, Human
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
Background: Researchers have found a new way to treat cancer using T cell therapy. The therapy used in this study is T Cell Receptor (TCR) Gene Therapy Targeting Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1), a cancer germline…
- Trial name
- NCT05035407
- Testing
- IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors
Kanitinib in Treating Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the safety , tolerability, pharmacokinetics of Kanitinib and determine the optimal dose in patients with recurrent or metastatic solid tumors.
- Trial name
- NCT02916095
- Testing
- Kanitinib
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
Pain; Bone Neoplasms; Neoplasm Metastasis
A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease
This study will assess the efficacy and safety of ibandronate (Bondronat), administered intravenously (IV) or orally (PO), in participants with malignant bone disease and moderate to severe pain.
- Trial name
- NCT02561039
- Testing
- Ibandronate
- Where
- 9 sites in Bulgaria
- Volunteers
- 97 people
- Sponsor
- Hoffmann-La Roche
Advanced or Metastatic Solid Tumors
A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
This is the first in human study of KK2260. In Part 1a, the maximum tolerated dose (MTD) will be determined while evaluating the safety and tolerability of KK2260 in patients with advanced or metastatic solid tumors (any cancer…
- Trial name
- NCT06248411
- Testing
- KK2260
- Where
- 14 sites in Japan
- Volunteers
- 189 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer
Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers
This phase I trial is studying the side effects and best dose of dovitinib lactate when given together with gemcitabine hydrochloride and capecitabine in treating patients with advanced or metastatic solid tumors or advanced…
- Conditions
- Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT01497392
- Testing
- dovitinib lactate, gemcitabine hydrochloride, capecitabine
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Roswell Park Cancer Institute
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
This study was conducted to advance new treatment for patients with metastatic or locally advanced cancers expressing Neurotensin receptor 1 (NTSR1).
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Gastric Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT03525392
- Testing
- 177Lu-3BP-227 (also called 177Lu-IPN01087)
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 14 people
- Sponsor
- Ipsen
Supportive Care, Metastatic Cancer
Feasibility of Supportive Care Needs in Patients With Advanced Solid Cancer in a Therapeutic Trial
The purpose of the study is to assess the supportive care needs of patients enrolled in a therapeutic trial for metastatic cancer.
- Conditions
- Supportive Care, Metastatic Cancer, Clinical Trial
- Trial name
- ES4-UIC (NCT04896099)
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Institut Curie
Locally Advanced Solid Tumor, Metastatic Solid Tumor
A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations
The primary objective of this study is to evaluate the safety and tolerability of TY-2136b and to determine the recommended phase 2 dose (RP2D), with dose-escalation stage and dose-expansion stage.
- Trial name
- NCT05769075
- Testing
- TY-2136b
- Where
- 2 sites in United States
- Volunteers
- 282 people
- Sponsor
- TYK Medicines, Inc
Solid Tumors
A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC
This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and PK of vantictumab when combined with docetaxel.
- Trial name
- NCT01957007
- Testing
- Docetaxel, vantictumab
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Non-small Cell Lung Cancer, Esophageal Cancer
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery.
- Conditions
- Non-small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT02838836
- Testing
- Study sample collection
- Where
- United States
- Volunteers
- 620 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Metastatic dMMR Solid Cancer, Solid Tumor
Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy
To evaluate the efficacy of sirolimus by estimating the overall response rate (ORR) as assessed by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1) in patients with metastatic dMMR solid cancer after…
- Conditions
- Metastatic dMMR Solid Cancer, Solid Tumor, Cancer, Metastatic Solid Tumor
- Trial name
- NCT04393454
- Testing
- Sirolimus 2mg Tablet
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Albert Einstein College of Medicine
Advanced Solid Tumor
Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies
The goal of this study is to determine whether a significant pharmacokinetic interaction exists between rapamycin and sorafenib.
- Trial name
- NCT00449280
- Testing
- Sorafenib, Rapamycin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Chicago
Advanced Cancer
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
This is an open-label, multi-center, Phase I trial of TST001. Subjects with locally advanced or metastatic solid tumors will be enrolled.
- Trial name
- NCT04495296
- Testing
- TST001, Oxaliplatin, Capecitabine
- Where
- 40 sites in China
- Volunteers
- 320 people
- Sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
Metastatic Solid Tumors (Any Localization)
Exploratory Clinical Study of ¹⁷⁷Lu-CTR-FAPI in Patients With Metastatic Solid Tumors
This is a single-center, non-randomized, single-arm, open-label exploratory clinical study of ¹⁷⁷Lu-CTR-FAPI in patients with FAP-high expressing metastatic solid tumors, with a focus on breast cancer, sarcoma, and thyroid…
- Trial name
- NCT07587996
- Testing
- radionuclide therapy with ¹⁷⁷Lu-CTR-FAPI
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Lanzhou University Second Hospital
Osteosarcoma, Bone Metastases
A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy
This is a dose finding study of a novel radiopharmaceutical agent, 153Sm-DOTMP. It will be studied alone and then in combination with external beam radiotherapy. The study design includes six cohorts, Levels 1-6.
- Trial name
- NCT03612466
- Testing
- 153Sm-DOTMP, External beam radiotherapy., Calcium Carbonate
- Where
- United States
- Sponsor
- Albert Einstein College of Medicine
Advanced Cancers, Melanoma
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
The goal of this clinical research study is to find the highest tolerable dose of MGN1703 that can be given in combination with ipilimumab to patients with advanced tumors.
- Trial name
- NCT02668770
- Testing
- MGN1703, Ipilimumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.